Track record · closed signal

AstraZeneca PLC (AZN) — closed signal from May 4, 2026

Partial Published before the outcome was known, scored automatically when the window closed on August 2, 2026 — -7.9% at the close.

Predicted vs. what happened

AZN price · publication thesis → realized outcomesplit-adjusted

$180.00 – $186.00Entry zone — fair-value band

$184.13Published — price the day we called it

$209.90Target — the price the thesis aimed for

$196.41Peak — highest point inside the window, not a realized return

$169.64Window close — end-of-window price, context only

What happened

Partial

Reached 48% of the predicted growth at its peak, without hitting the target.

At window close

-7.9%

realized, from the publication price to the last close inside the window

Peak gain

+6.7%

peak, from the publication price — not a realized return

S&P 500, same window

+4.3%

SPY over the identical days, dividend-adjusted

Window close

$169.64

last close inside the window, ended August 2, 2026

Peak price

$196.41

peak on July 2, 2026 — not a realized return

Days to target

—

The thesis — published May 4, 2026

Predicted growth

+14%

over the measurement window

Target price

$209.90

the price the thesis aimed for

Entry zone

$180.00 – $186.00

the fair-value band we waited for

Price at publication

$184.13

published May 4, 2026

Confidence

75%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

AstraZeneca is a steady healthcare company that looks positioned to recover after a recent drop. Strong first-quarter results and slightly better guidance help, but split FDA panel votes for cancer drugs mean regulatory results could limit near-term gains. The company's wide mix of medicines makes it resilient; still, expected profit growth is only modest so the short-term case stays cautious.

Primary drivers

Better-than-expected Q1 results and raised guidance
Broad drug lineup provides steady revenue sources
Conflicting FDA panel votes raise approval and timing risk
Recent sell-off leaves scope for a recovery move

How it played out

AZN: recovery fell short of the target

Lyra published a cautious short-term recovery thesis for AstraZeneca at 184.13, with 14% expected growth and a 209.90 target. The thesis pointed to better-than-expected first-quarter results, raised guidance, a broad drug lineup, and room to recover after a sell-off. It also flagged conflicting FDA panel votes and modest expected profit growth.

The price rose to a 196.41 peak on July 2, a 6.7% gain, but it never reached the 209.90 target. By August 2, it had fallen to 169.64, below the publication price and the entry zone. The recovery part of the thesis played out for a time, but the full call missed because the target was not reached and the window ended lower.

What happened during the window

On July 9, 2026, AstraZeneca said the CARDIO-TTRansform Phase III trial for Wainua did not meet its primary efficacy endpoint. On July 27, the company reported that first-half revenue rose 6% and core earnings per share rose 11% at constant exchange rates.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AZN signals